JKAYThanks jkay, nice post and embedded link.
FINALLY a poster who gets it!
A few things:
1) dilution won’t be a problem long term, Ryplazim and 4050 are blockbusters in the making, what is lost now through dilution will come back to Investors 10 fold plus.
2) Alstrom Syndrome is the gold standard (“the acid test”) of fibrosis, control the fibrosis for Alstrom patients and you’ll control the WW fibrotic market $$$, 4050 reverses fibrosis in six organs: heart, lung, liver, pancreas, kidneys, and skin, no other drug can currently make that claim.
3) I saw the “short attack” as a gift, a buying/share accumulation opportunity.
4) “great science, bad financial management”, I don't buy that statement either jay!
5) PL knows what they have, I know what they have, and after the Alstrom phase 2 results the pharmaceutical industry knows what Prometic has.
6) I don’t see Prometic lasting long, I see a buy out after 4050 is marketed WW around 2021.
gl2u